Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may
be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of …

Essentials• Direct oral anticoagulants (DOACs) do not require laboratory monitoring
currently.• DOAC specific measurements were performed at trough in patients with atrial …

INTRODUCTION: Rivaroxaban does not require monitoring nor frequent dose adjustment.
However, searching for the optimal dose in the individual patient may be useful in some …

Apixaban does not require monitoring nor frequent dose adjustment. However, searching for
the optimal dose for the individual patient may be useful in some situations. Moreover, there …

Introduction Direct oral anticoagulant (DOAC) intra-and inter-individual variability was
previously reported, but its magnitude is still considered negligible for patient management …

Essentials• Currently, DOACs are given at fixed doses and do not require laboratory
monitoring.• Direct oral anticoagulant‐specific measurements were performed at trough and …

Rivaroxaban is an oral, direct factor Xa inhibitor. Routine coagulation monitoring is not
required, but a quantitative determination of rivaroxaban concentrations might be useful in …